Polaryx Therapeutics, Inc. Cash and Cash Equivalents
Polaryx Therapeutics, Inc. (PLYX) had Cash and Cash Equivalents of $11.54 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $11.54M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $3.08M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $5.14M.
- 2024-12-31: Cash and Cash Equivalents, at Carrying Value $4.62M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $11.54M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.08M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $5.14M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $4.62M 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |